Back to News
Market Impact: 0.2
Vertex Pharmaceuticals (VRTX) Misses Q3 Earnings Estimates
Source: zacks.com
Corporate EarningsAnalyst EstimatesCompany Fundamentals
Vertex Pharmaceuticals reported quarterly earnings of $4.76 per share, below the Zacks Consensus Estimate of $4.92. Earnings were also down from $4.80 per share a year earlier.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
VRTX-0.45
More News
- Vertex Pharma meets Q3 estimates, raises revenue guidance
- Neurocrine earnings in focus as Ingrezza pricing pressure looms
- Vertex faces earnings test as kidney drugs near key milestones
- Weekly earnings outlook: mega-cap tech, AI hardware and healthcare in focus
- Vertex Reports Third Quarter 2026 Financial Results
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet